Inovio Pharmaceuticals Inc. closed $12.66 below its 52-week high ($14.75), which the company reached on April 1st.

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses.

Stephens has recently initiated Inovio Pharmaceuticals Inc (INO) stock to Overweight rating, as announced on May 14, 2024, according to Finviz. Earlier, on January 25, 2024, Oppenheimer had raised the ...

Inovio Pharmaceuticals Inc. closed $12.47 short of its 52-week high ($14.75), which the company reached on April 1st.

Inovio Pharmaceuticals shares are trading higher by 20.7% Tuesday afternoon. Vaccine stocks are rising amid growing concerns ...

The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.

State Street Corp raised its position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Free Report) by 11.7% in the third quarter, Holdings Channel.com reports. The institutional investor owned 490,662 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Inovalis REIT is an intriguing speculative opportunity. It's had a horrible past few years of performance and is now a penny ...

Latest on INO: Exclusive BAC Article: Inovio Pharmaceuticals; BLA Filing INO-3107 For RRP 2nd Half Of 2024, GBM Program Update INO-5401 1st Half Of 2024 And Catalysts ...

26.79% of the stock is owned by institutional investors. 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever INO has been the ...